Short answer
Akebia Therapeutics, Inc. (AKBA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter results for period ended September 30, 2026 announced.
Akebia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter results for period ended September 30, 2026 announced
- Recent business highlights included alongside financial results
- Investor-relevant figures and management commentary available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $36.9M, down from $58.8M, driven by Auryxia revenue falling to $20.0M amid generic competition
- Vafseo revenue $14.8M, while active patients reached approximately 11,500, up 140% year over year
- Vafseo growth offset by customer inventory reduction and TDAPA expiration approaching, creating near-term revenue volatility
- Net loss $14.4M versus $0.5M net income, despite SG&A falling to $23.5M from $29.1M
- Cash $159.3M, down from $184.8M at December 31, with management targeting at least two years of funding and term-loan refinancing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Akebia Therapeutics, Inc. 8-K filings
Get the next AKBA 8-K as it lands
Follow AKBA for push alerts, or ask the research agent what this filing means.